TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37119186

Group type: EXPERIMENTAL
Intervention: Coronary care unit patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discharged patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New coronary care unit mortality score
Number of subjects: 0
Study: 37119208

Group type: EXPERIMENTAL
Intervention: Broadest definition of relapse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PIRA (6-month confirmed disability worsening without relapse)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PIA (progression independent of any inflammatory activity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two CDW events (not relapse)
Number of subjects: 0
Study: 37119264

Group type: EXPERIMENTAL
Intervention: Bonded retainer 13-23
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bonded retainer 12-22
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Removable vacuum-formed retainer
Number of subjects: 90
Study: 37119314

Group type: EXPERIMENTAL
Intervention: Nilotinib plus pegylated interferon-α2b
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 0
Study: 37119322

Group type: EXPERIMENTAL
Intervention: HPI guided GDT protocol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (GDT protocol aimed at SVI optimization)
Number of subjects: 60
Study: 37119480

Group type: EXPERIMENTAL
Intervention: Stable isotope labeling paired with mass spectrometry to evaluate in vivo protein kinetics and concentration of soluble SOD1 in cerebrospinal fluid (CSF).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurement of deaminated SOD1 peptide, SDGPVKV, correlating with protein stability.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stable isotope labeling approaches and peptide deamidation.
Number of subjects: 0
Study: 37119510

Group type: EXPERIMENTAL
Intervention: Endoscopic therapy for gastric, duodenal, ampullary and rectal pouch polyps
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemopreventive therapies targeting FAP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin and non-steroidal anti-inflammatories (NSAIDs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endoscopic management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complementary use of chemopreventive agents and endoscopic therapy
Number of subjects: 0
Study: 37119523

Group type: EXPERIMENTAL
Intervention: T-DM1 (trastuzumab emtansine)
Number of subjects: 284
Study: 37119829

Group type: EXPERIMENTAL
Intervention: Urinary DKK3 above the median (>1689 pg/mg creatinine)
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Intensified blood pressure control in children with urinary DKK3 >1689 pg/mg creatinine
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Inhibition of the renin-angiotensin-aldosterone system
Number of subjects: 659
Study: 37119868

Group type: EXPERIMENTAL
Intervention: Integrated treatment for depression and smoking (12-week intervention)
Number of subjects: 300
Study: 37119871

Group type: EXPERIMENTAL
Intervention: Nummular Eczema (NE)
Number of subjects: 50
Study: 37120027

Group type: EXPERIMENTAL
Intervention: Routine radiation therapy with LLNs inside the clinical target volume (CTV)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Routine radiation therapy with LLNs outside the clinical target volume (CTV)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Routine radiation therapy with LLNs receiving ≥95% of planned dose
Number of subjects: 223

Group type: COMPARATOR
Intervention: Routine radiation therapy with LLNs receiving <95% of planned dose
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Dose escalation of 60 Gy
Number of subjects: 223
Study: 37120031

Group type: EXPERIMENTAL
Intervention: Bulevirtide (BLV) monotherapy
Number of subjects: 21
Study: 37120135

Group type: EXPERIMENTAL
Intervention: HLA-haploidentical related donor bone marrow transplantation (haplo-BMT)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Unrelated umbilical cord blood transplantation (UCBT)
Number of subjects: 368
Study: 37120136

Group type: EXPERIMENTAL
Intervention: Omidubicel
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard UCB
Number of subjects: 37
Study: 37120460

Group type: EXPERIMENTAL
Intervention: BEAT Cancer intervention
Number of subjects: 222

Group type: COMPARATOR
Intervention: Written materials (control)
Number of subjects: 222
Study: 37120509

Group type: EXPERIMENTAL
Intervention: Pediatric Medication Therapy Management (pMTM) intervention
Number of subjects: 296

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 296
Study: 37120522

Group type: EXPERIMENTAL
Intervention: CNV analysis in mGluR network genes
Number of subjects: 15689
Study: 37120538

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37120593

Group type: EXPERIMENTAL
Intervention: Venetoclax (100 mg on day 1, 200 mg on day 2, and 400 mg on days 3-14) combined with azacitidine (75 mg/m2) and homoharringtonine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Venetoclax combined with azacitidine and homoharringtonine
Number of subjects: 96
Study: 37120600

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC) - four cycles of 5-min pressure cuff inflation at 250 mmHg and deflation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 50
Study: 37120671

Group type: EXPERIMENTAL
Intervention: SRA737 800 mg QD
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: SRA737 1000 mg QD
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: SRA737 1300 mg QD
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: SRA737 monotherapy
Number of subjects: 107
Study: 37120736

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg once-daily
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 37120774

Group type: EXPERIMENTAL
Intervention: Subthreshold EPM PRP
Number of subjects: 70

Group type: COMPARATOR
Intervention: Threshold PRP
Number of subjects: 70
Study: 37120800

Group type: EXPERIMENTAL
Intervention: PARENT intervention (community health worker as health educator); mean score for parent-reported receipt of recommended anticipatory guidance: 73.9 (SD, 23.4)
Number of subjects: 937

Group type: COMPARATOR
Intervention: Usual care; proportion with ≥2 ED visits: 36.1%
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: PARENT intervention; increased psychosocial assessments, greater number of developmental or behavioral concerns addressed, increased attendance at well-child visits, greater parental experiences with care
Number of subjects: 937
Study: 37120902

Group type: EXPERIMENTAL
Intervention: Daily enteral lipid supplementation with arachidonic acid (AA):docosahexaenoic acid (DHA) (100:50 mg/kg/day)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Intravenous lipid emulsion containing olive oil:soybean oil (4:1)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Total phospholipid fatty acids
Number of subjects: 204
Study: 37121237

Group type: EXPERIMENTAL
Intervention: Indobufen (100 mg tablet twice per day)
Number of subjects: 5438

Group type: COMPARATOR
Intervention: Aspirin (100 mg tablet once per day)
Number of subjects: 5438

Group type: EXPERIMENTAL
Intervention: Indobufen
Number of subjects: 5438

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 5438

Group type: EXPERIMENTAL
Intervention: Indobufen and Aspirin
Number of subjects: 5438
Study: 37121331

Group type: EXPERIMENTAL
Intervention: EUS-guided choledocho-duodenostomy (ECDS)
Number of subjects: 155

Group type: COMPARATOR
Intervention: ERCP with covered metallic stents
Number of subjects: 155
Study: 37121354

Group type: EXPERIMENTAL
Intervention: Low-intensity transcranial ultrasound stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study: 37121359

Group type: EXPERIMENTAL
Intervention: R-RALP with retroperitoneal CO2 insufflation
Number of subjects: 21
Study: 37121391

Group type: EXPERIMENTAL
Intervention: High-definition (HD) videobronchoscopy
Number of subjects: 134
Study: 37121390

Group type: EXPERIMENTAL
Intervention: Cooking Matters for Diabetes (6-week diabetes and culinary education intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health Impact Ohio Central Ohio Pathways Hub intervention (community health worker model)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Referral to the Mid-Ohio Farmacy (weekly access to fresh produce)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All interventions combined
Number of subjects: 0
Study: 37121533

Group type: EXPERIMENTAL
Intervention: 12-month PrI prevention intervention led by an occupational therapist
Number of subjects: 232

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 232
Study: 37121835

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage with frankincense and myrrh essential oils
Number of subjects: 91

Group type: COMPARATOR
Intervention: Massage with jojoba oil
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (no massage)
Number of subjects: 91
Study: 37121850

Group type: EXPERIMENTAL
Intervention: avelumab + best supportive care (BSC)
Number of subjects: 700

Group type: COMPARATOR
Intervention: best supportive care (BSC)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: avelumab + BSC
Number of subjects: 700
Study: 37121865

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 317
Study: 37122050

Group type: EXPERIMENTAL
Intervention: Weight-based HFNC (max flow of 2 L/kg per minute)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard HFNC (max flow of 8 L per minute)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Weight-based HFNC with protocolized weaning
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard HFNC
Number of subjects: 51
Study: 37122357

Group type: EXPERIMENTAL
Intervention: NUC and HBIG prophylaxis after OLT
Number of subjects: 31
Study: 37122487

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for 8 weeks
Number of subjects: 214
Study: 37122489

Group type: EXPERIMENTAL
Intervention: Falling Safely Training (FAST) program for 4 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Evidence-based balance training (modified Otago exercise program)
Number of subjects: 28
Study: 37122809

Group type: EXPERIMENTAL
Intervention: SB2 treatment in IFX-naïve patients
Number of subjects: 1233

Group type: EXPERIMENTAL
Intervention: SB2 treatment in IFX ref patients
Number of subjects: 1233

Group type: EXPERIMENTAL
Intervention: SB2 treatment in IFX bs patients
Number of subjects: 1233
Study: 37123045

Group type: EXPERIMENTAL
Intervention: PD-1 blockade
Number of subjects: 0
Study: 37123046

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 37124199

Group type: EXPERIMENTAL
Intervention: Machine learning-based detection system for medication errors
Number of subjects: 0
Study: 37124204

Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37124504

Group type: EXPERIMENTAL
Intervention: Human intravital microscopy
Number of subjects: 0
Study: 37124558

Group type: EXPERIMENTAL
Intervention: Hybrid sinus node-sparing ablation procedure
Number of subjects: 142
Study: 37124637

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 567

Group type: COMPARATOR
Intervention: LDCT
Number of subjects: 567
Study: 37124726

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE), 75 mg intramuscularly/month for 6 months
Number of subjects: 27

Group type: COMPARATOR
Intervention: Testosterone undecanoate (TU), 250 mg intramuscularly every 3 months for 6 months
Number of subjects: 27
Study: 37124732

Group type: EXPERIMENTAL
Intervention: ω3-LCPUFAs (500-mg soft capsules, 0.100 g/kg of body weight/day for three months)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: ω3-LCPUFAs
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (sunflower oil)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 37125046

Group type: EXPERIMENTAL
Intervention: Low carbohydrate high fat diet (LCHF)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Vegan, vegetarian, and omnivorous diets
Number of subjects: 130
Study: 37125397

Group type: EXPERIMENTAL
Intervention: High dose vitamin D (5000 IU/day)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Low dose vitamin D (600 IU/day)
Number of subjects: 172
Study: 37125459

Group type: EXPERIMENTAL
Intervention: Daprodustat 4 mg tablets manufactured via twin-screw wet granulation (process 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daprodustat tablets manufactured via process 1 (1, 2, 4, 6, and 8 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daprodustat tablets manufactured via process 2 (1, 2, 4, 6, and 8 mg)
Number of subjects: 0
Study: 37125484

Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37125490

Group type: EXPERIMENTAL
Intervention: SA4Ag vaccine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 37125500

Group type: EXPERIMENTAL
Intervention: L-citrulline + Glutathione (Setria Performance Blend: SPB; L-citrulline [2 g] + glutathione [200 mg], 6 capsules)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (PL; 3.1 g cellulose, 6 capsules)
Number of subjects: 25
Study: 37125529

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan 200 mg
Number of subjects: 1129

Group type: COMPARATOR
Intervention: ramipril 5 mg
Number of subjects: 1129
Study: 37125809

Group type: EXPERIMENTAL
Intervention: Bundled consent and expectation setting (experimental group)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Standard consent for invasive procedures (control group)
Number of subjects: 261
Study: 37125811

Group type: EXPERIMENTAL
Intervention: Prehospital tranexamic acid (TXA)
Number of subjects: 766

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 766
Study: 37125831

Group type: EXPERIMENTAL
Intervention: Eat, Sleep, Console approach
Number of subjects: 1305

Group type: COMPARATOR
Intervention: Usual care (Finnegan tool)
Number of subjects: 1305
Study: 37125884

Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation intervention consisting of weekly play sessions at home for 9 months, along with iron treatment for 6 months for IDA group.
Number of subjects: 372

Group type: COMPARATOR
Intervention: Control group (non-intervention) for IDA children.
Number of subjects: 372
Study: 37125891

Group type: EXPERIMENTAL
Intervention: Integrated Early Childhood Development program delivered through community, group, and home-visiting platforms over 12-15 months.
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: Integrated Early Childhood Development program
Number of subjects: 1790
Study: 37125901

Group type: EXPERIMENTAL
Intervention: Low-resolution tomography Z-score neurofeedback (LZNFB)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Theta/beta neurofeedback (theta/beta NFB)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 87
Study: 37125968

Group type: EXPERIMENTAL
Intervention: LAWT-guided pulmonary vein antrum isolation
Number of subjects: 121
Study: 37126021

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 10
Study: 37126069

Group type: EXPERIMENTAL
Intervention: Positron emission tomography/CT after intravenous administration of 296±20% MBq
Number of subjects: 0
Study: 37126135

Group type: EXPERIMENTAL
Intervention: Implementation of the CHARM study
Number of subjects: 364
Study: 37126208

Group type: EXPERIMENTAL
Intervention: Work-loop contractility model using human cardiomyocytes
Number of subjects: 0
Study: 37126326

Group type: EXPERIMENTAL
Intervention: Transplantation
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Death
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Prognostic factors for transplant
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Prognostic factors for death
Number of subjects: 96
Study: 37126332

Group type: EXPERIMENTAL
Intervention: Xuebijing injection (100 mL, intravenous infusion every 12 hours for 5 days)
Number of subjects: 1817

Group type: COMPARATOR
Intervention: Placebo (volume-matched saline, intravenous infusion every 12 hours for 5 days)
Number of subjects: 1817

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1817

Group type: EXPERIMENTAL
Intervention: Xuebijing injection
Number of subjects: 1817
Study: 37126338

Group type: EXPERIMENTAL
Intervention: Multimodal transitional care intervention including systematic medication reconciliation, a 15-minute patient education session with teach-back, a planned first follow-up visit with their primary care physician, and postdischarge follow-up telephone calls at 3 and 14 days.
Number of subjects: 1386

Group type: COMPARATOR
Intervention: Usual care from hospitalist plus a 1-page standard study information sheet.
Number of subjects: 1386
Study: 37126378

Group type: EXPERIMENTAL
Intervention: mHealth+I (n=74)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: mHealth (n=71)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control (n=76)
Number of subjects: 221
Study: 37126399

Group type: EXPERIMENTAL
Intervention: Intranasal testosterone gel 11 mg 3 times daily
Number of subjects: 81

Group type: COMPARATOR
Intervention: Intramuscular testosterone cypionate 200 mg every 2 weeks
Number of subjects: 81
Study: 37126507

Group type: EXPERIMENTAL
Intervention: Non-slip socks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Barefoot (Control)
Number of subjects: 0
Study: 37126599

Group type: EXPERIMENTAL
Intervention: Minding the Baby® (MTB), an attachment-based home visiting intervention
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study: 37126739

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (600 mg EPA and 300 mg DHA, twice daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 37126770

Group type: EXPERIMENTAL
Intervention: Lenalidomide (regimen A, low-dose 20 mg/m2)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Lenalidomide (regimen B)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Lenalidomide (regimen A)
Number of subjects: 74
Study: 37127045

Group type: EXPERIMENTAL
Intervention: Fractional dose (one-fifth of the standard dose) of 17D-213 yellow fever vaccine
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard dose of 17D-213 yellow fever vaccine
Number of subjects: 250
Study: 37127047

Group type: EXPERIMENTAL
Intervention: Fractional dose (one-fifth) of 17D-213 yellow fever vaccine
Number of subjects: 420

Group type: COMPARATOR
Intervention: Standard dose of 17D-213 yellow fever vaccine
Number of subjects: 420
Study: 37127041

Group type: EXPERIMENTAL
Intervention: Pandemic decrease phase (June 1 to Dec 31, 2021)
Number of subjects: 22974

Group type: COMPARATOR
Intervention: Pandemic escalation phase (March 1, 2020 to May 31, 2021)
Number of subjects: 22974
Study: 37127211

Group type: EXPERIMENTAL
Intervention: Purse-string uterine suture
Number of subjects: 126

Group type: COMPARATOR
Intervention: Double-layer continuous unlocked suture
Number of subjects: 126
Study: 37127210

Group type: EXPERIMENTAL
Intervention: Advanced oral hygiene regimen (antibacterial mouth wash, dental floss, antibacterial toothpaste, power toothbrush, intensive oral hygiene education)
Number of subjects: 613

Group type: COMPARATOR
Intervention: Usual oral hygiene care (standard oral home care instructions and regimen)
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Advanced oral hygiene regimen
Number of subjects: 613

Group type: COMPARATOR
Intervention: Usual oral hygiene care
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Advanced oral hygiene regimen among unemployed participants with less favorable socioeconomic status
Number of subjects: 613

Group type: COMPARATOR
Intervention: Usual oral hygiene care among unemployed participants with less favorable socioeconomic status
Number of subjects: 613
Study: 37127523

Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 vaccine
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 37127526

Group type: EXPERIMENTAL
Intervention: Sabin strain inactivated poliovirus vaccine (sIPV)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Wild strain poliovirus vaccine (wIPV)
Number of subjects: 500
Study: 37127558

Group type: EXPERIMENTAL
Intervention: vonoprazan 20 mg for 4-8 weeks, then 10 mg for maintenance
Number of subjects: 208

Group type: COMPARATOR
Intervention: lansoprazole 30 mg for 4-8 weeks, then 15 mg for maintenance
Number of subjects: 208
Study: 37127595

Group type: EXPERIMENTAL
Intervention: Telehealth exercise intervention (30-60 min/session, 3 sessions/week)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Delayed control
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Telehealth exercise intervention
Number of subjects: 20
Study: 37127632

Group type: EXPERIMENTAL
Intervention: HEMO2life® (1 g/l preservation solution)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (routine preservation solution)
Number of subjects: 0
Study: 37127657

Group type: EXPERIMENTAL
Intervention: 0.2 mg naldemedine daily for 12 months
Number of subjects: 120

Group type: COMPARATOR
Intervention: Matching placebo for 12 months
Number of subjects: 120
Study: 37127683

Group type: EXPERIMENTAL
Intervention: Early removal of postoperative drains 3 hours after surgery in the absence of contraindications
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional chest drain management
Number of subjects: 72
Study: 37127754

Group type: EXPERIMENTAL
Intervention: CBP/p300 HAT inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Investigational KAT6A/B HAT inhibitor
Number of subjects: 0
Study: 37127822

Group type: COMPARATOR
Intervention: Standard care (n=20)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Calorie restriction (25% energy reduction; n=21)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Calorie restriction and exercise three times per week (n=20)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Calorie restriction and exercise six times per week (n=21)
Number of subjects: 82
Study: 37128722

Group type: EXPERIMENTAL
Intervention: Self-reported African American race
Number of subjects: 2427

Group type: COMPARATOR
Intervention: Demographics, health status, and socioeconomic status adjustments
Number of subjects: 2427
Study: 37128727

Group type: EXPERIMENTAL
Intervention: Stellate ganglion block (Group S)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 40